Screening pathway Sample Clauses

Screening pathway. ‌ The NHSP pathway consists of the following: Identify eligible population • all eligible babies, born or resident in England, should be offered a newborn hearing screen before 3 months corrected age for prematurity (see section 3.14 for details of exclusion criteria). It is expected that all reasonable efforts will be made to ensure that babies have their screen completed before they move area from the one in which they were born • the eligible population of ‘new births’ or ‘new registrations’ is identified through a birth notification into the NHSP national IT system or notification to the screening team by the local child health records department (CHRD) • the local maternity services, or in exceptional cases the CHRD, is responsible for entering high quality, timely data into the NHS number registration system (Patient Demographic System) to enable electronic identification of babies eligible for screening within the national IT system. This should be completed as soon as possible after birth and ideally prior to any newborn screening being performed (i.e. NIPE/NHSP/NBS) • where a NHS number has not been generated for any reason the provider should have systems in place to identify these eligible babies and undertake screening without delay • a mechanism should be in place to identify babies who move into the area under three months of age who have not been screened. The local screening programme must be informed of these babies by child health/health visitor/primary care
AutoNDA by SimpleDocs
Screening pathway. A full description of the screening pathway is given below, along with a diagram of the pathway. Providers must be familiar with the screening pathway and the timeframes in which to refer women (figure 1). The fetal anomaly screening pathway consists of the following: • identify population - the eligible population is identified through maternity services. For fetal anomaly screening the eligible population are women less than or equal to 23+0 weeks of pregnancy confirmed by ultrasound scan • inform - during the ‘first contact’ or ‘booking visit’ with the midwife, verbal and written information should be given about the fetal anomaly scan (using NHS Screening programmes booklet ‘Screening Tests for You and Your Baby’) to enable women to make a personal informed choice. • offer - the offer of screening and subsequent acceptance or decline must should be documented in the patient held record/maternity notes (paper or electronic) • test - the fetal anomaly ultrasound scan should be performed between 18+0 to 20+6 weeks gestation. Where the image quality of the first scan is compromised a single further scan should be offered by 23+0 weeks gestation • the fetal anomaly ultrasound scan should be performed to comply with the requirements of the anatomical base menu and fetal cardiac protocol which are detailed in the programme handbook. • a local failsafe protocol must be in place to ensure that all women who accept fetal anomaly screening complete the testing pathway Management of results: No anomaly suspected: all women should be notified of their scan findings at the time of the screen. The results should be documented in the patient held record/maternity notes (paper or electronic). Anomaly suspected: the woman is informed at the time of the scan and the sonographer/ midwife/clinician and woman discuss the options available

Related to Screening pathway

  • Screening 3.13.1 Refuse containers located outside the building shall be fully screened from adjacent properties and from streets by means of opaque fencing or masonry walls with suitable landscaping.

  • Treatment Program Testing The Employer may request or require an employee to undergo drug and alcohol testing if the employee has been referred by the employer for chemical dependency treatment or evaluation or is participating in a chemical dependency treatment program under an employee benefit plan, in which case the employee may be requested or required to undergo drug or alcohol testing without prior notice during the evaluation or treatment period and for a period of up to two years following completion of any prescribed chemical dependency treatment program.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act.

  • Library CONTRACTOR shall provide an inmate law library in compliance with Rule 33-501.301, F.A.C., FDC’s Policy 501.301, and ACA Standards.

  • Cutting, Patching, and Fitting The Contractor shall do all cutting, patching, and fitting of the Work that may be required to make its several parts come together properly and fit.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

Time is Money Join Law Insider Premium to draft better contracts faster.